Simeprevir
- Generic Name
- Simeprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C38H47N5O7S2
- CAS Number
- 923604-59-5
- Unique Ingredient Identifier
- 9WS5RD66HZ
- Background
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patie...
- Indication
Indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated ...
- Associated Conditions
- Chronic Hepatitis C Genotype 1, Genotype 4 Chronic Hepatitis C
- Associated Therapies
- -
Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01907724
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT01852604
Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2016-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01813513
Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
- Conditions
- Interventions
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT01628692
- Locations
- 🇪🇸
Local Institution, Valencia, Spain
🇺🇸Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸San Francisco General Hospital, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.